drugset / Trial / NCT00755755

PGL4001 Versus Placebo in Uterine Myomas

NCT00755755

Phase 3 Completed 241 enrolled PregLem SA
RandomizedParallel-groupDouble-blindTreatment

Summary

This trial will assess the efficacy and safety of PGL4001 with concomitant iron administration versus placebo with concomitant iron administration, over a 3-month period for the pre-operative treatment of pre-menopausal women suffering from excessive uterine bleeding due to uterine myoma.

Timeline

Start
2008-10
Primary completion
2010-03
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Ulipristal Acetate Unknown 5 mg Oral
Subject Ulipristal Acetate Unknown 10 mg Oral
Background Iron Sulfate Small molecule 80 mg Oral

Indications